Such off-target effects of the FAK inhibitors may contribute to their efficacy in cancer and may also make them efficacious in rheumatoid arthritis, despite the fact that depletion of FAK alone appears to have no effect in synovial fibroblast migration or arthritis. The gene discussed is PTK2; the disease is arthritic joint disease.